Antihypertensive Effects of Two Novel Angiotensin I-Converting Enzyme (ACE) Inhibitory Peptides from Gracilariopsis lemaneiformis (Rhodophyta) in Spontaneously Hypertensive Rats (SHRs)

Mar Drugs. 2018 Aug 27;16(9):299. doi: 10.3390/md16090299.

Abstract

A variety of biologically active products have been isolated from Gracilariopsis lemaneiformis. In the present study, two novel angiotensin-converting enzyme (ACE) inhibitory peptides, FQIN [M(O)] CILR, and TGAPCR, were screened and identified from G. lemaneiformis protein hydrolysates by LC-MS/MS. The IC50 values of FQIN [M(O)] CILR and TGAPCR were 9.64 ± 0.36 μM and 23.94 ± 0.82 μM, respectively. In the stability study, both peptides showed stabilities of pH, temperature, simulated gastrointestinal digestion, and ACE hydrolysis. The Lineweaver⁻Burk plot showed that the two peptides were noncompetitive inhibitors of ACE. Molecular docking simulated the intermolecular interactions of two peptides and ACE, and the two peptides formed hydrogen bonds with the active pockets of ACE. However, FQIN [M(O)] CILR was more closely linked to the active pockets of ACE, thereby exerting better ACE inhibition. Spontaneously hypertensive rats (SHRs) were studied with an oral dose of 10 mg/kg body weight. Both peptides reduced systolic blood pressure (SBP) and diastolic blood pressure (DBP) in SHRs, of which FQIN [M(O)] CILR was able to reduce the systolic blood pressure by 34 mmHg (SBP) (p < 0.05). Therefore, FQIN [M(O)] CILR was an excellent ACE inhibitory peptide.

Keywords: ACE-inhibitory activity; Gracilariopsis lemaneiformis; SHRs; molecular docking; peptide.

MeSH terms

  • Administration, Oral
  • Angiotensin-Converting Enzyme Inhibitors / chemistry
  • Angiotensin-Converting Enzyme Inhibitors / pharmacology*
  • Angiotensin-Converting Enzyme Inhibitors / therapeutic use
  • Animals
  • Antihypertensive Agents / chemistry
  • Antihypertensive Agents / pharmacology*
  • Antihypertensive Agents / therapeutic use
  • Biological Products / chemistry
  • Biological Products / pharmacology
  • Biological Products / therapeutic use
  • Blood Pressure / drug effects
  • Disease Models, Animal
  • Drug Evaluation, Preclinical
  • Humans
  • Hypertension / drug therapy*
  • Male
  • Molecular Docking Simulation
  • Peptides / chemistry
  • Peptides / pharmacology*
  • Peptides / therapeutic use
  • Peptidyl-Dipeptidase A / chemistry
  • Protein Hydrolysates / chemistry
  • Rats
  • Rats, Inbred SHR
  • Rhodophyta / chemistry*
  • Tandem Mass Spectrometry

Substances

  • Angiotensin-Converting Enzyme Inhibitors
  • Antihypertensive Agents
  • Biological Products
  • Peptides
  • Protein Hydrolysates
  • Peptidyl-Dipeptidase A